Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

1.

Recombinant DNase in cystic fibrosis: a protocol for targeted introduction through n-of-1 trials. Scottish Cystic Fibrosis Group.

Böllert FG, Paton JY, Marshall TG, Calvert J, Greening AP, Innes JA.

Eur Respir J. 1999 Jan;13(1):107-13.

PMID:
10836333
[PubMed - indexed for MEDLINE]
Free Article
2.

In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.

Shah PL, Scott SF, Knight RA, Marriott C, Ranasinha C, Hodson ME.

Thorax. 1996 Feb;51(2):119-25.

PMID:
8711640
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group.

Harms HK, Matouk E, Tournier G, von der Hardt H, Weller PH, Romano L, Heijerman HG, FitzGerald MX, Richard D, Strandvik B, Kolbe J, Kraemer R, Michalsen H.

Pediatr Pulmonol. 1998 Sep;26(3):155-61.

PMID:
9773909
[PubMed - indexed for MEDLINE]
4.

Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis.

Ranasinha C, Assoufi B, Shak S, Christiansen D, Fuchs H, Empey D, Geddes D, Hodson M.

Lancet. 1993 Jul 24;342(8865):199-202.

PMID:
8100928
[PubMed - indexed for MEDLINE]
5.

Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.

McCoy K, Hamilton S, Johnson C.

Chest. 1996 Oct;110(4):889-95.

PMID:
8874241
[PubMed - indexed for MEDLINE]
6.

Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment.

Shah PI, Bush A, Canny GJ, Colin AA, Fuchs HJ, Geddes DM, Johnson CA, Light MC, Scott SF, Tullis DE, et al.

Eur Respir J. 1995 Jun;8(6):954-8.

PMID:
7589382
[PubMed - indexed for MEDLINE]
Free Article
7.

Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.

Shah PL, Scott SF, Fuchs HJ, Geddes DM, Hodson ME.

Thorax. 1995 Apr;50(4):333-8.

PMID:
7785003
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

The role of dornase alfa in the treatment of cystic fibrosis.

Cramer GW, Bosso JA.

Ann Pharmacother. 1996 Jun;30(6):656-61. Review.

PMID:
8792953
[PubMed - indexed for MEDLINE]
9.

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME.

N Engl J Med. 1994 Sep 8;331(10):637-42.

PMID:
7503821
[PubMed - indexed for MEDLINE]
Free Article
10.

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.

Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl ME, Konstan MW; Pulmozyme Early Intervention Trial Study Group.

J Pediatr. 2001 Dec;139(6):813-20.

PMID:
11743506
[PubMed - indexed for MEDLINE]
11.

Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?

van der Giessen LJ, Gosselink R, Hop WC, Tiddens HA.

Eur Respir J. 2007 Oct;30(4):763-8. Epub 2007 Jun 27.

PMID:
17596273
[PubMed - indexed for MEDLINE]
Free Article
12.

Clinical trials of recombinant human DNase in cystic fibrosis patients.

Aitken ML.

Monaldi Arch Chest Dis. 1993 Dec;48(6):653-6.

PMID:
8124306
[PubMed - indexed for MEDLINE]
13.

[Multicenter study of rhDNase in cystic fibrosis with severe pulmonary involvement].

Hodson M.

Arch Pediatr. 1995 Jul;2(7):679-81. French.

PMID:
7663660
[PubMed - indexed for MEDLINE]
14.

Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study.

Nasr SZ, Kuhns LR, Brown RW, Hurwitz ME, Sanders GM, Strouse PJ.

Pediatr Pulmonol. 2001 May;31(5):377-82.

PMID:
11340684
[PubMed - indexed for MEDLINE]
15.

Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study.

Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A.

JAMA. 1992 Apr 8;267(14):1947-51.

PMID:
1548827
[PubMed - indexed for MEDLINE]
16.

Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis.

Costello CM, O'Connor CM, Finlay GA, Shiels P, FitzGerald MX, Hayes JP.

Thorax. 1996 Jun;51(6):619-23.

PMID:
8693445
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease.

Cimmino M, Nardone M, Cavaliere M, Plantulli A, Sepe A, Esposito V, Mazzarella G, Raia V.

Arch Otolaryngol Head Neck Surg. 2005 Dec;131(12):1097-101.

PMID:
16365224
[PubMed - indexed for MEDLINE]
18.

Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.

Shak S.

Chest. 1995 Feb;107(2 Suppl):65S-70S. Review.

PMID:
7842816
[PubMed - indexed for MEDLINE]
19.

Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial.

Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Normand C, Thompson S, Bush A, Wallis C.

Lancet. 2001 Oct 20;358(9290):1316-21.

PMID:
11684212
[PubMed - indexed for MEDLINE]
20.

Effect of rhDNase on lung function and quality of life in adult cystic fibrosis patients.

Heijerman HG, van Rossem RN, Bakker W.

Neth J Med. 1995 Jun;46(6):293-7.

PMID:
7643945
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk